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Abstract The complex communities of microorganisms
that colonise the human gastrointestinal tract play an
important role in human health. The development of cul-
ture-independent molecular techniques has provided new
insights in the composition and diversity of the intestinal
microbiota. Here, we summarise the present state of the art
on the intestinal microbiota with specific attention for the
application of high-throughput functional microbiomic
approaches to determine the contribution of the intestinal
microbiota to human health. Moreover, we review the
association between dysbiosis of the microbiota and both
intestinal and extra-intestinal diseases. Finally, we discuss
the potential of probiotic microorganism to modulate the
intestinal microbiota and thereby contribute to health and
well-being. The effects of probiotic consumption on the
intestinal microbiota are addressed, as well as the devel-
opment of tailor-made probiotics designed for specific
aberrations that are associated with microbial dysbiosis.
Keywords Diversity  Dysbiosis  Host-microbe
interactions  Intestinal microbiota  Probiotics
Introduction
It is known for over three decades that the human body
contains tenfold more microbial cells (1014) than human
cells (Savage 1977). These microorganisms colonise
practically every surface of the human body that is exposed
to the external environment, including the skin, oral cavity,
respiratory, urogenital and gastrointestinal tract. Of these
body sites, the gastrointestinal (GI) tract is by far the most
densely colonised organ. The complex community of
microorganisms residing in or passing through the GI tract
is referred to as the intestinal microbiota.
The intestinal microbiota plays a role in metabolic,
nutritional, physiological and immunological processes in
the human body. It exerts important metabolic activities by
extracting energy from otherwise indigestible dietary
polysaccharides such as resistant starch and dietary fibres.
These metabolic activities also lead to the production of
important nutrients, such as short-chain fatty acids (SCFA),
vitamins (e.g. vitamin K, vitamin B12 and folic acid) and
amino acids, which humans are unable to produce them-
selves (Hamer et al. 2008; Wong et al. 2006). In addition,
the intestinal microbiota participates in the defence against
pathogens by mechanisms such as colonisation resistance
and production of antimicrobial compounds. Furthermore,
the intestinal microbiota is involved in the development,
maturation and maintenance of the GI sensory and motoric
functions, the intestinal barrier and the mucosal immune
system. These are just a few examples of the functional
contributions of the intestinal microbiota to human health,
a subject that is regularly reviewed (Barbara et al. 2005;
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Cerf–Bensussan and Gaboriau–Routhiau 2010; O’Hara
and Shanahan 2006; Sekirov et al. 2010; Zoetendal et al.
2008).
In recent years, a sharp increase is seen in the number of
publications addressing the intestinal microbiota. They
have provided various lines of evidence supporting a close
link between the intestinal microbiota and human health.
This review aims to summarise the current knowledge on
the composition and diversity of the intestinal microbiota.
In addition, it is discussed how new molecular approaches
have provided novel insights towards the phylogenetic and
functional characterisation of the intestinal microbiota.
Furthermore, recent insights on the link between the
intestinal microbiota and human health are provided.
Finally, an overview is presented of ways to modulate the
intestinal microbiota with specific attention for the use of
probiotics, defined as live microorganisms which, when
administered in adequate amounts, confer a health benefit
on the host (FAO/WHO 2002).
Microbial diversity in the GI tract
The GI tract is a complex and dynamic ecosystem con-
taining a diverse collection of microorganisms. These
microorganisms are either resident members of the intes-
tinal microbiota or transient passengers introduced from
the environment, for example by the regularly influx of
microorganisms by the intake of food.
Compositional diversity of the intestinal microbiota
The intestinal microbiota can be described in richness
(‘who is present’) and evenness (‘with how many are they
present’) that together form the ecological terms of diver-
sity. If applied at the species-level, richness describes the
number of species present in a specific ecosystem, not
taking into account their relative abundance. This contrasts
with evenness, which represents the relative abundance of
each species in a specific ecosystem. These definitions are
used to describe the microbial diversity in the GI tract.
Up till recently, conventional culture-based methods
were used to assess the intestinal microbial diversity. Over
400 bacterial species have been successfully isolated, cul-
tured and characterised from the human GI tract (Rajilic´-
Stojanovic´ et al. 2007). However, these culture-based
methods have proven to be inadequate in determining the
true microbial diversity of the intestinal microbiota since a
large fraction of the microbiota remains uncultivated. For a
more accurate analysis of the compositional diversity of the
intestinal microbiota culture-independent approaches have
been developed and it has been revealed that the human
intestinal microbiota is an even more complex ecosystem
than previously expected. Most of these techniques target
the highly conserved 16S ribosomal RNA (rRNA) gene
sequences of bacterial and archaeal microorganisms.
Molecular techniques that are used to study the diversity of
the intestinal microbiota include quantitative polymerase
chain reaction (qPCR), temperature or denaturing gradient
gel electrophoresis (TGGE or DGGE), terminal-restriction
fragment length polymorphism (T-RFLP) and fluorescent
in situ hybridisation (FISH). The latest developments in
high-throughput technologies, such as next generation
sequencing and phylogenetic micro-arrays, now allow
more in-depth analysis of the complete phylogenetic
diversity of the intestinal microbiota (Van den Bogert et al.
2011; Zoetendal et al. 2008). Moving beyond the analysis
of the variation in the sequence of a single marker gene, it
is currently also possible to characterise the complete
genetic material obtained from environmental samples
such as the GI tract. With the aid of large-scale sequencing
approaches these so called metagenomes can be studied
and so far several metagenomic inventories of the intestinal
microbiota have been reported (Table 1).
Since the first application of culture-independent meth-
ods to determine diversity, it has been shown that the
composition of the intestinal microbiota varies substan-
tially amongst individuals (Zoetendal et al. 1998). At least





Sequencing technology Total length of
sequences obtained (Gb)
References
American 2 Sanger 0.2 Gill et al. (2006)
Japanese 13 Sanger 0.727 Kurokawa et al. (2007)
American 18 454 FLX Titanium 2.14 Turnbaugh et al. (2009)
European (Danish or Spanish) 124 Solexa (Illumina) 576.7 MetaHIT Qin et al. (2010)
European 20 Sanger 2.6 Genescope
French 49 SoliD 200 INRA
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part of this diversity can be attributed to genetic differences
amongst hosts. A positive relation between similarity in
dominant faecal microbial communities and genetic related-
ness of the hosts has been observed (Stewart et al. 2005;
Turnbaugh et al. 2009; Zoetendal et al. 2001). It is esti-
mated that more than 1,000 species-level phylotypes can be
found in the GI tract of the total human population (Qin
et al. 2010; Rajilic´-Stojanovic´ et al. 2007). However, the
phylogenetic diversity in one individual is much lower,
since the intestinal microbiota of each individual only
consists of approximately 160 different bacterial species
(Qin et al. 2010). This estimation is based on metagenomic
analysis using the number of non-redundant genes con-
tained by an average-sized genome. Despite the high
species richness and inter-individual variability of the
intestinal microbiota, a limited number of bacterial phylo-
types is more prevalent amongst individuals and might
therefore represent a shared phylogenetic core (Qin et al.
2010; Tap et al. 2009). However, the estimation of the size
of the phylogenetic core is dependent on the minimal rel-
ative abundance of a given phylotype that can be detected
by the molecular approaches deployed. Recent analysis of
metagenomic data indicated that there is a high variability
in relative abundance (evenness) of core phylotypes
amongst individuals (12- to 2,200-fold difference) (Qin
et al. 2010). Altogether, these results demonstrate that an
accurate estimation of the size of the phylogenetic core is
still difficult to make as this is highly dependent on the
depth of the analysis.
The vast majority of all microbial cells in the human GI
tract are bacteria. At the phylum-level, both culture-
dependent and independent studies have demonstrated that
the majority of the intestinal bacteria belong to two phyla,
the Bacteroidetes and the Firmicutes (Mariat et al. 2009).
The phylum Bacteroidetes consists of three classes, of
which the class Bacteroidetes, containing the well-known
genera Bacteroides and Prevotella, is probably the most
well studied. The Firmicutes is currently the largest bacte-
rial phylum, which contains more than 200 genera. The
majority of the Firmicutes detected in the GI tract fall pri-
marily into two main groups, the Clostridium coccoides
group (also known as Clostridium cluster XIVa) and the
Clostridium leptum group (also referred to as Clostridium
cluster IV) (Collins et al. 1994; Mariat et al. 2009). Both
groups contain members of the genera Clostridium,
Eubacterium and Ruminococcus that are taxonomically
polyphyletic. In addition to the two phyla Bacteroidetes and
Firmicutes, also members of other phyla, such as Proteo-
bacteria, Actinobacteria, Fusobacteria, Spirochaetes,
Verrucomicrobia and Lentisphaerae, have been detected
(Rajilic´-Stojanovic´ et al. 2007; Zoetendal et al. 2008).
Although bacteria dominate the GI tract ecosystem,
species from the archaeal domain can also be found in the
GI tract, with the methanogens, Methanobrevibacter smi-
thii and Methanosphaera stadtmanae being by far the most
dominant archaeal groups (Gill et al. 2006; Mihajlovski
et al. 2008). While it was previously assumed that these
methanogens were only present in a minor fraction of
healthy subjects, application of new DNA isolation meth-
ods has led to the observation that they are in fact highly
prevalent (Dridi et al. 2009; Salonen et al. 2010b). In
addition to bacteria and archaea, eukaryotic micro-
organisms can also be members of the intestinal micro-
biota. Culture-independent analysis of the fungal diversity
in the GI tract has demonstrated that the majority of the
phylotypes belonged to the two fungal phyla Ascomycota
(which includes the genera Candida and Saccharomyces)
and Basidiomycota (Ott et al. 2008; Scanlan and Marchesi
2008).
Microbial diversity along the GI tract
Host physiology and intestinal microbiota are intimately
connected. This is evident from the fact that each distinct
anatomical region along the GI tract is characterised by its
own physicochemical conditions, and that these changing
conditions exert a selective pressure on the microbiota. The
physicochemical conditions that influence the composition
of the intestinal microbiota include intestinal motility, pH,
redox potential, nutrient supplies, host secretions (e.g.
hydrochloric acid, digestive enzymes, bile and mucus), and
the presence of an intact ileocaecal valve (Booijink et al.
2007). Thus, the GI tract harbours many distinct niches,
each containing a different microbial ecosystem that varies
according to the location within the GI tract. This is already
demonstrated by the fact that the microbial density
increases along the GI tract. Per gram of intestinal content,
the microbial density increases from 101–104 microbial
cells in the stomach and duodenum, 104–108 cells in the
jejunum and ileum, to 1010–1012 cells in the colon and
faeces (Booijink et al. 2007; Dethlefsen et al. 2006).
Despite the fact that it is well known that the intestinal
microbiota is not homogeneously distributed within the GI
tract, it is still largely unknown how the diversity varies in
the different niches along the GI tract (‘who is present
where’).
By far, the most detailed knowledge is available with
respect to the microbial composition of faeces. This is
mainly because faecal material can be collected non-
invasively and contains a large biomass of microbial cells.
However, as it is increasingly acknowledged that the
composition of microbiota differs significantly in the dif-
ferent niches, more efforts are undertaken to determine the
spatio-temporal dynamics of the microbial diversity along
the whole GI tract (Zoetendal et al. 2002). The large
intestine has a rather uniform composition of luminal
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intestinal microorganisms, and faecal material seems to
represent the colonic microbiota composition best (Eck-
burg et al. 2005). In contrast, there is only limited insight in
the composition of the microbiota that resides in the small
intestine. Especially the lower part of the small intestine,
the ileum, has received minimal attention, mainly due to
sampling difficulties caused by the inaccessibility of this
region (Booijink et al. 2007). The composition of the small
intestinal microbiota is largely influenced by a combination
of gastric acid, bile and pancreatic secretions that enter the
GI tract in the duodenum, and which together create a
harsh environment for most microorganisms (Booijink
et al. 2007). Hence, compared with other regions, few
microorganisms are able to inhabit the upper part of the GI
tract. In addition, the antegrade peristaltic movements as
part of the migrating motor complex (MMC) ensure a
relatively short passage time through the small intestine
(3–5 h) by pushing the microbiota towards the large
intestine, thus leaving limited time for microorganisms to
replicate and increase in numbers (Booijink et al. 2007).
The short passage time allows transitioning bacteria to
retain viability. Furthermore, cellular enzymes such as
glutamate decarboxylase and bile resistance systems offer
protection against the low pH and bile salts encountered in
this upper part of the GI tract, respectively (Audia et al.
2001; Merritt and Donaldson 2009).
The small intestine is the part of the GI tract where most
of the host enzymatic digestion of the food occurs. The
products of these digestive activities are absorbed in more
distal parts of the small intestine, the jejunum and espe-
cially the ileum. The conditions in the ileum are more
favourable for microbial growth compared with the
proximal part of the small intestine, as for example the pH
is less acidic and bile acids are reabsorbed. Therefore, the
number of microorganisms in the ileum can be higher
compared with the duodenum (Booijink et al. 2007).
Most of the knowledge about the small intestinal mic-
robiota has been derived from studies with ileal biopsies
collected during surgical intervention (Ahmed et al. 2007;
Baumgart et al. 2007; Wang et al. 2003, 2005; Willing
et al. 2009) or from samples obtained from elderly indi-
viduals at autopsy (Hayashi et al. 2005). In addition, ileal
effluent from ileostomy patients has been used to study the
diversity of the luminal microbiota of the human ileum
(Booijink et al. 2010; Hartman et al. 2009). It was shown
that the composition of the microbiota in ileostomy effluent
clearly differs from that of the faecal microbiota. Com-
pared with faecal microbiota, ileostomy effluent microbiota
is less diverse and less stable, since large fluctuations in
ileal microbiota profiles per individual were observed over
time (Booijink et al. 2010). One of the main findings of this
study by Booijink and colleagues was that ileostomy
effluent showed a higher relative abundance of species
within the orders Lactobacillales and Clostridiales, espe-
cially Veillonella- and Streptococcus-related phylotypes
(Booijink et al. 2010). In addition, species belonging to
Clostridium cluster I were detected in high levels, in con-
trast with the reduced levels of species belonging to the
Bacteroidetes and Clostridium clusters III, IV and XIVa.
More recently, it was demonstrated that the microbiota
composition of ileostomy effluent, which is characterised
by an abundance in Streptococcus and Veillonella species,
is more similar to the proximal small intestinal microbiota
and clearly differs from that of the ileum (Zoetendal et al.
2011).
In addition to the variation in microbial composition
along the GI tract, the microbiota present in the intestinal
lumen also differs significantly from that attached to and
imbedded in the intestinal mucus layer. Since mucosa-
associated microorganisms live in close contact with host
cells, it is likely they execute different functions within the
GI ecosystem compared with luminal microorganisms.
Several studies have reported a significant difference in
dominant microbial community composition between
colonic biopsies and faecal samples in humans (Eckburg
et al. 2005; Lepage et al. 2005; Zoetendal et al. 2002). It
should be kept in mind, however, that in these studies
colonic biopsies were obtained from humans undergoing
standard colonoscopy, which in general is preceded by a
laxative preparation in order to clean the GI tract. The
influence of this procedure on the luminal and mucosa-
associated microbiota is still largely unknown (Mai et al.
2006).
Animal models could provide a means to study both the
microbial composition along the GI tract as well as the
difference in luminal and mucosa-associated microbiota,
without the need for physiological alterations during sam-
pling. It has been demonstrated in rodents that intestinal
microorganisms are able to survive and even proliferate in
the outer loose mucus layer since the glycans present in this
layer are accessible as energy source for these micro-
organisms (Kim and Ho 2010; Johansson et al. 2010). In
contrast, the inner stratified firmly attached mucus layer
probably prevents the intestinal bacteria from coming in
contact with the colonic epithelial cells (Johansson et al.
2008). The organisation of the mucus layers varies amongst
the different parts of the GI tract, as it has been observed
that the mucus layers in the stomach and the colon are well
defined, in contrast to the small intestine where the mucus
is less evenly distributed (Atuma et al. 2001; Johansson
et al. 2010). Most likely, such differences in mucus layer
organisation will be associated with variation in the
mucosa-associated microbiota along the GI tract. A recent
study in mice has shown that the dominant microbiota
composition of proximal colonic mucosa-associated and
faecal microbiota are very similar to each other, but differ
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both significantly from distal colonic mucosa-associated
samples (Wang et al. 2010). In addition, the study demon-
strated that the region-specific mucosa-associated microbiota
determines the region-specific expression of host genes, in
this case of genes encoding Toll-like receptors (TLRs).
Due to the application of culture-independent molecular
approaches, our knowledge of the intestinal microbiota has
been advanced significantly (Zoetendal et al. 2006). Yet, a
complete description of the microbial diversity along the
human GI tract cannot be given at this moment. Future
research should include more samples from the various
distinct niches along the GI tract, which nowadays can be
collected using minimally invasive methods and which can
be deeply analysed using high-throughput technologies.
Functional diversity of the intestinal microbiota
Recently, the collective genome of the human intestinal
microbiota (the human intestinal microbiome) was estimated
to contain 3.3 million microbial genes, which is*150 times
more genes than the human genome (Qin et al. 2010). The
presence of this wide array of genes in addition to our own
genome, suggests that a profound influence of intestinal
microorganisms on the human body can be expected. This
means that meaningful information related to human health
does not only originate from insights in the compositional
diversity (‘who is present’, ‘with how many are they present’
and ‘who is present where’), but can also be derived from
knowledge on the function of the microbiota (‘what are they
doing’). The extent to which the intestinal microbiota is able
to expand the metabolic, nutritional, physiological and
immunological functions the host is able to perform, is still
largely unknown. To address this question, metagenomic
studies can provide information on the diversity of the genes
encoded by the intestinal microbiota. Recently, it was cal-
culated that almost 40% of the microbial genes present in
each human individual were shared with at least half of the
human individuals in the studied cohort. These data provide
evidence for the existence of a functional core (core micro-
biome) (Qin et al. 2010). Since functional redundancy
within members of the intestinal microbiota exists, there is
the possibility that the phylogenetic core does not fully
correspond to the functional core (Zoetendal et al. 2008). The
functional core may contain shared metabolic functions (e.g.
degradation of sugar monomers, production of vitamins or
butyrate formation) as well as sequential pathways which
would, respectively, restrict or expand functional diversity
irrespective of phylogenetic diversity.
A main focus of current research is to understand the
functional contribution of the human intestinal microbiota
to the host. Function-driven metagenomics is a first step in
assessing the functional capacity of the intestinal micro-
biota. A prediction of the functional capacity can originate
from the metagenome by comparing the assembled
sequences to reference databases, such as the COG (clusters
of orthologous groups) and KEGG (Kyoto encyclopedia of
genes and genomes) databases. Moreover, function-driven
metagenomics can be applied to assign a function to
predicted gene products and can even contribute to gene
discovery (Tasse et al. 2010; Cowan et al. 2005). The first
metagenomic studies have demonstrated that, compared
with the human genome, the human intestinal microbiome
is highly enriched for COG and KEGG categories involved
in metabolism (Gill et al. 2006; Kurokawa et al. 2007;
Turnbaugh et al. 2009). Pathways involved in metabolism
of energy, amino acids, nucleotides, carbohydrates, cofac-
tors and vitamins, terpenoids and polyketides, and the bio-
synthesis of secondary metabolites are highly represented in
the human microbiome. These pathways not only allow the
microbes to generate energy, to grow and proliferate, but
also to influence the host. Some of the metabolites are being
taken away from the host while other ones are provided (e.g.
SCFA, vitamins, gases). Overall, the (metabolic) interaction
between microbes and host is beneficial for both parties.
Future studies should provide data to further establish and
detail the functional contribution of the intestinal micro-
biota to the metabolic capacity of the host.
Metagenomic studies provide only insight in the genetic
potential of the intestinal microbiota and do not demon-
strate its true functional contribution to the maintenance of
health and well-being (Zoetendal et al. 2008). In order to
obtain insights in the in situ expression of genes encoded
by the intestinal microbiome, other functional microbiomic
approaches, such as metatranscriptomics, metaproteomics
and metabolomics are required. A recent example of a
metatranscriptomic approach to study the intestinal micro-
biota is provided by the study performed by Booijink
et al. (2010). These authors were able to demonstrate that
the gene expression of the human faecal microbiota is
subject-specific and enriched for genes involved in (car-
bohydrate) metabolism. Gosalbes and colleagues also
applied a metatranscriptomic approach to study the func-
tionality of the faecal microbiota of healthy volunteers
(Gosalbes et al. 2011). Remarkably, more rRNA genes
were observed than protein-encoding genes. Analysis of
the latter showed a uniform functional pattern in carbo-
hydrate metabolism, energy production and synthesis of
cellular components as well as regulatory elements (small
RNAs). More specific information has been derived from
the metatranscriptomic analysis of bifidobacteria in early
life that revealed marked differences between breast-fed
and formula-fed infants. Moreover, the specific expression
of genes involved in the degradation of human-derived
sugars and vitamins such as folic acid biosynthesis testify
for the health impacting function of intestinal bifidobac-
teria (Klaassens et al. 2009). Furthermore, metaproteomics
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approaches have been applied to investigate faecal samples
obtained from human infants (Klaassens et al. 2007) and
adults (Rooijers et al. 2011; Verberkmoes et al. 2009). In
human adults, it was demonstrated that the faecal meta-
proteome is enriched in proteins belonging to the COG
categories involved in translation, energy production and
carbohydrate metabolism (Verberkmoes et al. 2009).
Compared with metatranscriptomics and metaproteomics
approaches, metabolomic approaches have up to this date
been applied more frequently, using NMR spectroscopy
and mass spectroscopy in conjunction with computational
multivariate analysis (Nicholson and Lindon 2008). A
recent study by Martin and colleagues demonstrates that
metabolic profiling can be used for studying nutrient-
microbiota relations by examining the effects of dietary
intervention on the presence of faecal metabolites (Martin
et al. 2010). A variety of systemic diseases such as
hypertension (Holmes et al. 2008) and diabetes (Dumas
et al. 2007) appear to be directly influenced by microbial
metabolism in model animals and human (Kinross et al.
2011). The metabolic pathways that are involved in drug
metabolism are also influenced by the intestinal microbiota
in an in vitro system (Aura et al. 2011).
Altogether, functional microbiomic approaches can be
applied to examine microbial gene expression and to estab-
lish the effects of microbial gene products on the host.
However, up to this date it is difficult to connect functionality
to the presence of individual microbial species in the human
GI tract. In order to link specific sets of genes to the presence
of distinct microbial species, complete microbial genome
sequences will be needed. Several independent research
consortia have taken up the effort to sequence the genomes of
hundreds of bacterial strains, which together will form a
catalogue of reference genomes from the human microbiota.
Recently, the initial sequencing of 178 reference genomes
was reported and the first results of comparative genomic
analysis of these sequences provided important insight into
the inter-strain diversity of bacterial genomes (Nelson et al.
2010). Large-scale functional microbiomic analyses are
needed to fully understand the impact of the human
microbiome on the host. This means that a larger number of
samples, deeper sequencing, longer sequence reads and more
extensive comparative analyses are needed. Integration of all
these microbiomic approaches will help to define the func-
tional contribution of each individual microbial phylotype in
the human GI tract to the health status of the host.
Changes in composition and diversity of the intestinal
microbiota are related to disease
The type and number of microbial species that persist and
colonise the GI tract is not determined by chance, but by a
combination of factors including but not limited to the
inflammatory state of the host, diet, host genetics, and
environmental factors (Buddington and Sangild 2011;
Cerf–Bensussan and Gaboriau–Routhiau 2010; Hansen
et al. 2010; Musso et al. 2010). This means that the host
itself influences the composition of the intestinal micro-
biota. However, the relative impact of these factors on the
intestinal microbiota is still largely unknown.
The intestinal microbiota and the host have co-
evolved (Ley et al. 2008). Human evolution has taken
place amidst a world of microorganisms. Symbiotic
microorganisms have occupied the niches offered by the
gastrointestinal tract and probably adapted to the local
circumstances. This in turn may have influenced human
evolution in terms of metabolic and nutritional require-
ments. Ultimately, man depends on its intestinal micro-
biota for a number of vital functions and thus these
intestinal microorganisms may contribute to health. It is,
however, difficult to describe the precise impact of the
intestinal microbiota on human health and the involve-
ment in human disease.
Perturbation of the microbiota composition, also known
as dysbiosis, has been recognised in various diseases, of
which many are associated with the GI tract. However,
before dysbiosis can be established, the composition of a
healthy ‘normal’ microbiota has to be defined. Yet, the
definition of a healthy microbiota is not easy to give.
From an operational point of view it could be stated that a
healthy intestinal microbiota is the microbiota composi-
tion as it can be found in healthy individuals. For prac-
tical reasons, the phylogenetic characterisation of the
microbiota of diseased individuals in comparison with
apparently healthy individuals is, at this moment, the
main approach to study changes in composition of the
intestinal microbiota in relation to disease. However,
since there are substantial inter-individual and intra-
individual variations in the composition of the intestinal
microbiota, it is difficult to establish the precise relations
between human health and the presence and relative
abundance of specific microbial communities. In the
future, specific changes in compositional diversity, or
even functional diversity, may be applied as biomarkers
for health or specific diseases. It must be noted, however,
that it is questionable whether changes in phylogenetic
composition are really cause or consequence of a given
disease.
A role for the intestinal microbiota in the pathogenesis
of several diseases and disorders has been suggested.
Intensively studied examples for which dysbiosis of the
intestinal microbiota has been described, include inflam-
matory bowel disease (IBD), irritable bowel syndrome
(IBS) and obesity, which will be discussed in-depth in this
part of the review.
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The microbial composition at different stages of life
and its relation to health
The intestinal microbiota of healthy adult individuals is
relatively stable over time (Costello et al. 2009; Franks
et al. 1998; Vanhoutte et al. 2004; Zoetendal et al. 1998).
However, intra-individual fluctuations occur due to envi-
ronmental changes and pathological events. In addition,
substantial changes in the composition of intestinal
microbiota occur at both ends of life, in infants and elderly
individuals (Tiihonen et al. 2010; Vael and Desager 2009).
Since alterations in the microbial composition are recog-
nised to be of influence on human health, the interest in the
development and composition of the microbiota of infant
and elderly humans has significantly increased in the last
years.
It is widely accepted that microbial colonisation of the GI
tract starts during and directly after birth when neonates are
exposed to bacteria that are derived from the mother and the
surrounding environment (Adlerberth and Wold 2009;
Mackie et al. 1999). Yet, the human foetal environment is
not completely microbiologically sterile and there are
indications that non-pathological in utero exposure of the
foetus to intestinal bacteria or bacterial DNA frequently
occurs (Pettker et al. 2007; Satokari et al. 2009). In addition,
the isolation of bacteria from the meconium (the first stool
of the neonate), umbilical cord blood and amniotic fluid of
healthy neonates has been reported (Jime´nez et al. 2005,
2008). Postnatal colonisation of the GI tract is highly var-
iable amongst neonates and is influenced by several factors
including mode of delivery, type of infant feeding, gesta-
tional age, infant hospitalisation and antibiotic use (Penders
et al. 2006). It is, however, still unclear how each of these
factors exactly influences the infant microbial diversity and
how this is related to health. A disturbed development of the
infant microbiota has been associated with the development
of disease later in life (Vael and Desager 2009). For
example, associations have been made between dysbiosis in
infants and the later development of childhood obesity
(Collado et al. 2008b; Kallioma¨ki et al. 2008) and atopic
and allergic diseases (Bjo¨rkste´n et al. 2001; Kallioma¨ki
et al. 2001; Penders et al. 2007; Sjo¨gren et al. 2009; Wang
et al. 2008).
Several culture-independent studies have shown that
there is a large inter-individual variability amongst infants
in the development of the microbiota (Favier et al. 2002;
Palmer et al. 2007; Penders et al. 2006; Roger et al. 2010).
In addition, it has been demonstrated that the infant
microbiota is highly dynamic and develops in a step-wise
fashion with an increase in diversity over time (Palmer
et al. 2007; Roger et al. 2010). An important stage in the
colonisation of the GI tract of infants is the period in which
the infants feed on the milk they receive either by
breastfeeding or by infant-formula feeding. During this
period, the faecal microbiota of infants consists mainly of
bifidobacteria (Roger and McCartney 2010; Roger et al.
2010). Some bifidobacteria are highly adapted to the
digestion of the oligosaccharides present in human milk
(Zivkovic et al. 2010). The infant intestinal microbiota
contains a relatively low diversity in Bifidobacterium
populations; B. breve, B. bifidum and B. longum subsp.
infantis are the most common Bifidobacterium species
(Roger et al. 2010). Compared with breast-fed infants, the
intestinal microbiota of formula-fed infants is characterised
by less diverse Bifidobacterium populations (Roger et al.
2010) and more complex communities of Clostridia,
Enterobacteriaceae, Bacteroides and Enterococcus
(Harmsen et al. 2000; Penders et al. 2006). The introduc-
tion of solid food (weaning) marks an increase in microbial
diversity and changes in the microbial composition towards
an adult microbiota (Koenig et al. 2010). For example,
dominant Bifidobacterium populations change; B. adole-
scentis, B. catenulatum and B. longum subsp. longum are
more abundantly present in the adult microbiota (Matsuki
et al. 2004). The successive shifts of different microbial
communities within the first years of life ultimately result
in the development of an adult-like microbiota.
In the elderly (usually defined as people over the age of
65), there are major physiological changes that have an
impact on the composition and the functionality of the
intestinal microbiota (Tiihonen et al. 2010; Woodmansey
2007). Many elderly humans suffer from decreased intes-
tinal motility, which can result in prolonged intestinal
transit time and faecal retention. Age-related changes, such
as decreased senses for smell and taste, dental decay
and swallowing difficulties can lead to narrowing of the
nutritional intake and even malnutrition. In addition, the
age-related gradual deterioration of the immune system
(immunosenescence) is associated with changes in intesti-
nal microbiota composition (Schiffrin et al. 2010).
Furthermore, the increased use of laxatives, antibiotics and
other medication in elderly individuals will affect intestinal
microbiota composition.
Culture-independent studies have demonstrated that the
composition of the intestinal microbiota significantly
changes with age (Bartosch et al. 2004; Mariat et al. 2009;
Mueller et al. 2006; Zwielehner et al. 2009). Recently,
high-throughput methods have been applied to study the
changes in the intestinal microbiota of elderly individuals.
Biagi and colleagues have used the HITChip, a phylo-
genetic microarray specifically designed to study the human
GI tract microbiota, to compare the intestinal microbiota
composition of young adults with that of elderly indivi-
duals and centenarians. It was demonstrated that especially
the microbiota of centenarians showed significant differ-
ences compared with microbiota composition of the other
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two age groups (Biagi et al. 2010). The microbiota of
centenarians was characterised by low species-level
diversity, specific changes in Firmicutes subpopulations,
enrichment in Proteobacteria and a decrease in bifido-
bacteria. In addition, high-throughput next generation
sequencing has been used by Claesson and colleagues to
study the composition, variability and temporal stability of
the intestinal microbiota of the elderly (Claesson et al.
2010). They observed that the faecal microbiota of elderly
individuals was relatively stable over a 3 month period in
the majority of the subjects. However, compared with
younger control subjects, the microbiota of the elderly was
characterised by a high inter-individual variation in
microbiota composition, also at phylum level. The relative
abundance of the Firmicutes varied between 8% and 80%,
whereas the Bacteroidetes levels varied between 14% and
92%. Furthermore, it was found that in the majority of the
elderly subjects the microbiota was characterised by a
higher Bacteroidetes/Firmicutes ratio compared with that
observed in younger adults. In addition, distinct differences
were seen in Proteobacteria, Actinobacteria and Clos-
tridium populations between young and older adults. With
respect to human health, associations have been found
between microbiota composition and frailty in elderly
individuals (Van Tongeren et al. 2005). In frail elderly
persons, a significant reduction in the number of lacto-
bacilli, Faecalibacterium prausnitzii and Bacteroides-
Prevotella groups was seen. In contrast, the number of
Enterobacteriaceae was significantly higher. The number
of studies that have focused on the age-related differences
in intestinal microbiota composition is still limited. In
general, they suggest that maintenance of (microbial)
homeostasis in the GI tract is essential for healthy ageing.
Microbial diversity and IBS
IBS is a functional bowel disorder which is characterised
by recurrent abdominal pain or discomfort, irregular bowel
movements and disordered stool patterns such as consti-
pation or diarrhoea (Longstreth et al. 2006). The occur-
rence of these symptoms, however, can vary from person to
person. The aetiology of IBS is probably complex and still
not well understood. Several factors are thought to
be involved in IBS and may include altered GI motility,
visceral hypersensitivity, low-grade inflammation, and
psychosocial (anxiety and depression), genetic and dietary
factors (Chang and Talley 2011; Karantanos et al. 2010).
Several studies, using both culture-dependent and
independent methods, have demonstrated an association
between IBS and dysbiosis of the intestinal microbiota
(Table 2). In general, faecal material has been used to
study dysbiosis in IBS patients. However, more recently
also duodenal (Kerckhoffs et al. 2009, 2010) and colonic
(Carroll et al. 2010; Codling et al. 2010) biopsies have been
used to study the mucosa-associated microbiota. Most
studies aimed to show changes in the predominant micro-
bial communities, however, in some cases the focus was
more on specific microbial groups. Quantitative differences
in microbiota composition, even for specific microbial
groups, have been observed in IBD patients compared with
healthy individuals. However, the results of the various
studies are inconsistent and no consensus has been reached
on the association between specific microbial groups and
IBS, notably as the power of the studies was low and the
depth of the analysis was limited (Salonen et al. 2010a). At
the functional level, some studies have demonstrated
altered colonic fermentation patterns and increased gas
production in IBS patients (Koide et al. 2000; Mortensen
et al. 1987; Tana et al. 2010; Treem et al. 1996). However,
these results have not yet been confirmed in other studies at
the molecular level.
In most of the studies, IBS patients have been classified
into different subtypes based on Rome II criteria for IBS:
diarrhoea-predominant IBS (IBS-D), constipation-
predominant IBS (IBS-C) or a mixed type of IBS with
alternating stool patterns (IBS-A). Distinct changes in
microbiota composition have been observed in the different
IBS subtypes compared with healthy individuals (Malinen
et al. 2005; Maukonen et al. 2006; Lyra et al. 2009). It
appears that the intestinal microbiota of IBS-D patients
deviates the most from that of healthy individuals (Carroll
et al. 2010; Krogius–Kurikka et al. 2009). These data
demonstrate the relevance of clinical subtyping of IBS
patients when analysing the intestinal microbiota. So far,
however, the results from the studies which have applied
IBS subtyping have also not shown uniform changes in
microbial composition (Salonen et al. 2010a).
Microbial diversity and IBD
IBD is a collective name for chronic inflammatory disorders
of the GI tract, of which Crohn’s disease (CD) and ulcerative
colitis (UC) are the most prevalent forms. These are both
chronic and relapsing diseases that affect the intestinal
mucosa. For both CD and UC, the exact aetiology is still not
clear, however, it is has been suggested that an aberrant
immune response directed against intestinal microbial
antigens is involved (Hansen et al. 2010; Sartor 2008; Sokol
and Seksik 2010). CD affects the whole GI tract and is
characterised by discontinuous inflammation of the epithe-
lial lining and deep ulcers. UC on the other hand is restricted
to the colon and the rectum and is characterised by a con-
tinuous mucosal inflammation and superficial ulcers.
During the last decade, numerous culture-independent
studies have compared the intestinal microbiota composi-
tion of IBD patients with that of healthy individuals
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(Table 3). There is increasing evidence that dysbiosis of
the intestinal microbiota has a role in the pathogenesis of
IBD. Up to this date, however, the phylum-level changes
observed in IBD patients have not always been consistent.
In general, an overall decrease in microbial diversity and
stability of the intestinal microbiota has been observed in
IBD patients (Hansen et al. 2010). In addition, a decrease
in specific members of the Firmicutes has been reported in
IBD patients, which in some cases coincided with an
increase in Bacteroidetes and facultative anaerobes such as
Enterobacteriaceae (Hansen et al. 2010). Significant dif-
ferences exist in the microbiota composition of CD patients
compared with UC patients (Frank et al. 2007; Sokol et al.
2006). Recently, Joossens and colleagues identified a set of
five bacterial species that characterised the predominant
dysbiosis in CD patients compared with unaffected rela-
tives and healthy individuals (Joossens et al. 2011). These
five species are Dialister invisus, an uncharacterised
species of Clostridium cluster XIVa, Faecalibacterium
prausnitzii, Bifidobacterium adolescentis and Ruminococcus
Table 2 Overview of human studies that demonstrate an association between IBS and compositional dysbiosis of the intestinal microbiota
determined with culture-independent methods
Study material Population Analytical methods References
Faeces (3 time points) 27 IBS patients
22 Healthy individuals
qPCR Malinen et al. (2005)*




Clone library sequencing (16S)
Ma¨tto¨ et al. (2005)*
Biopsies: inflamed and non-inflamed
tissue (ileum, ascending/sigmoid colon)
20 CD patients
20 UC patients
20 Self-limiting colitis patients
20 IBS patients
20 Healthy individuals
FISH Swidsinski et al. (2005)




Maukonen et al. (2006)*
Faeces 24 IBS patients
23 Healthy individuals
G?C based profiling
Clone library sequencing (16S)
qPCR







Kerckhoffs et al. (2009)#
Faeces 10 (?2) IBS (only IBS-D)
23 Healthy individuals
G?C based profiling
Clone library sequencing (16S)
qPCR
Krogius–Kurikka et al. (2009)*
Faeces (3 time points) 20 IBS patients
15 Healthy individuals
qPCR Lyra et al. (2009)*
Colonic biopsies
Faeces















Clone library sequencing (16S)
qPCR
Kerckhoffs et al. (2010)#
Faeces 44 IBS patients qPCR Malinen et al. (2010)*





Tana et al. (2010)
All studies have applied Rome II or III criteria to recruit their subjects and categorise them in IBS subtypes. Studies that have used subjects from
the same cohort are indicated by * and #
DGGE denaturing gradient gel electrophoresis, FISH fluorescence in situ hybridisation, HPLC high-performance liquid chromatography, qPCR
quantitative polymerase chain reaction, TRAC transcript analysis with the aid of affinity capture
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Table 3 Overview of human studies that demonstrate an association between IBD and compositional dysbiosis of the intestinal microbiota
determined with culture-independent methods
Study material Population Analytical methods References
Biopsies (terminal ileum, colon) 12 CD patients (active disease)
12 UC patients (active disease)
14 Non-IBD controls
FISH Kleessen et al. (2002)
Biopsies: inflamed and non-inflamed
tissue (ileum, ascending/sigmoid
colon)
28 Self-limiting colitis patients







Swidsinski et al. (2002)
Faeces 8 CD patients (active disease)




Seksik et al. (2003)




Mangin et al. (2004)
Colonic biopsies: inflamed tissue 26 CD patients (active disease)







Ott et al. (2004)
Rectal biopsies: inflamed and
non-inflamed tissue
4 CD patients (active disease)
2 CD patients (in remission)
14 UC patients (active disease)
19 UC patients (in remission)
14 Non-IBD controls
FISH Mylonaki et al. (2005)





20 Self-limiting colitis patients
20 IBS patients
20 Non-IBD controls
FISH Swidsinski et al. (2005)




20 CD patients (active disease)






Bibiloni et al. (2006)









Gophna et al. (2006)












1 Ischemic colitis patient
15 Non-IBD controls
DGGE








DGGE Scanlan et al. (2006)
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Table 3 continued
Study material Population Analytical methods References
Faeces 13 CD patients (active disease)
13 UC patients (active disease)
5 Infectious colitis patients
13 Healthy individuals
FISH/flow cytometry Sokol et al. (2006)#
Faeces 29 UC patients (active disease)
12 UC patients (in remission)
46 Healthy individuals
T-RFLP Andoh et al. (2007)
Ileal biopsies 13 CD patients (ileum)






Baumgart et al. (2007)






Frank et al. (2007)





Kotlowski et al. (2007)
Faeces 17 CD patients (active disease)
17 CD patients (in remission)
20 Healthy controls
T-RFLP Andoh et al. (2008)
Faeces 10 Twin pairs with CD





Dicksved et al. (2008)
Faeces
(several time points)
16 UC patients (in remission)
8 Healthy controls
DGGE Martinez et al. (2008)
Colonic biopsies
Faeces
15 CD patients (active disease)
8 CD patients (in remission)
44 UC patients (active disease)





Takaishi et al. (2008)
Rectal biopsies: inflamed and
non-inflamed tissue
9 UC patients (active disease)
11 Non-IBD controls
T-RFLP Nishikawa et al. (2009)
Faeces 22 CD patients (active disease)
10 CD patients (in remission)
12 UC patients (active disease)
4 UC patients (in remission)
8 Infectious colitis patients
27 Healthy individuals
qPCR Sokol et al. (2009)#
Biopsies (terminal ileum, ascending/
transverse/descending colon,
rectum)
10 Twin pairs with CD





Willing et al. (2009)





Kang et al. (2010)*
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gnavus. Of these species, F. prausnitzii has been associated
with prolongation of remission in CD (see also below and
Sokol et al. 2008, 2009), while bifidobacteria in general
have shown to have beneficial effects on health (see
above). Most interestingly, the unaffected relatives of CD
patients also have a different composition of their pre-
dominant microbiota compared with healthy individuals in
general. The impact of these observations on IBD diag-
nostics and aetiology now has to be addressed.
The role of several different microorganisms in the
aetiology of IBD has been studied in more detail. Adherent-
invasive Escherichia coli (Darfeuille–Michaud 2002; Dar-
feuille–Michaud et al. 2004) and Mycobacterium avium
subspecies paratuberculosis (Rosenfeld and Bressler 2010)
are two prime suspects that have been implicated to be
involved in CD pathogenesis. However, a causal relation
has not yet been demonstrated. Recently, the presence of
two species belonging to the family Enterobacteriaceae,
Klebsiella pneumoniae and Proteus mirabilis, was corre-
lated with the development of colitis in a mouse model
(Garrett et al. 2010). The evidence that specific micro-
organisms can induce intestinal inflammation and cause
IBD is, however, still inconclusive, despite the considerable
amount of studies concerning this subject. In addition to the
identification of potential pathogenic bacteria, other bacte-
rial species have been suggested to protect against IBD. For
example, it has been shown that the relative abundance of
F. prausnitzii, a commensal bacterium with anti-inflam-
matory properties, is significantly decreased in CD patients
compared with healthy individuals (Sokol et al. 2008).
High-throughput metagenomic studies can provide
more insight in the composition and diversity of the
intestinal microbiota of IBD patients. IBD is amongst the
first diseases that have been the subject of metagenomic
investigation (Qin et al. 2010). Based on the relative
abundance of 155 microbial species (present in at least
one individual at a genome coverage of C1% in this study
population), it was possible to separate patients from
healthy individuals, and UC from CD patients (Qin et al.
2010). The next step is to compare the IBD subpopula-
tions with healthy individuals at microbial gene-level. On
average, 25% fewer genes could be detected in the faecal
samples of IBD patients compared with individuals not
suffering from IBD (Qin et al. 2010). These results sug-
gest that the microbiota of IBD patients has a lower
functional diversity compared with healthy individuals.
The intestinal microbiota in IBD patients produce reduced
amounts of SCFA, in particular butyrate, while sulphate
reduction (by sulphate-reducing bacteria) is increased
(Fava and Danese 2011). In the near future, metagenomic
studies like these will provide more insight in the shifts in
functionality which characterises the differences between
IBD patients and healthy individuals.
The observed compositional and functional changes in
IBD patients suggest that the intestinal microbiota plays an
important role in the aetiology and pathogenesis of IBD.
However, up to this date it is still unclear whether dysbiosis
is a direct cause for the inflammation in IBD, or merely the
result of a disturbed environment in the GI tract. In the
latter case, a role for the intestinal microbiota in disease
Table 3 continued
Study material Population Analytical methods References
Faeces 4 CD patients (in remission)




Qin et al. (2010)





Joossens et al. (2011)





Mondot et al. (2011)
Biopsies: inflamed and non-inflamed
tissue (ileum, ascending/transverse/
descending/sigmoid colon, rectum)
12 CD patients (active disease)





Walker et al. (2011)
Most of the studies used the Crohn’s disease activity index (CDAI; for CD) and/or the clinical activity index (CAI; for UC patients) to
assess disease activity in the subjects and to define active disease or remission. Studies that have used subjects from the same cohort are indicated
by *, # and 
DGGE denaturing gradient gel electrophoresis, FISH fluorescence in situ hybridisation, HPLC high-performance liquid chromatography, qPCR
quantitative polymerase chain reaction, RISA ribosomal intergenic spacer analysis, SSCP single strand conformation polymorphism, T-RFLP
terminal-restriction fragment length polymorphism, TGGE temperature gradient gel electrophoresis
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maintenance and severity is possible and will have to be
explored in the future.
Microbial diversity and obesity
Obesity is a complex disease characterised by excess body
fat accumulation. It has been associated with phylum-level
changes in the composition of the intestinal microbiota
(Table 4). An increase in the relative abundance of Firmi-
cutes and a reduction in the level of Bacteroidetes has been
observed in both obese mice (ob/ob) (Ley et al. 2005) and
humans (Ley et al. 2006). However, since the original
publication, a series of studies have failed to confirm the
study of Ley and colleagues and shown variable results with
respect to the compositional changes in the microbiota of
obese humans (Collado et al. 2008b; Duncan et al. 2008;
Kallioma¨ki et al. 2008; Nadal et al. 2009; Santacruz et al.
2009, 2010; Schwiertz et al. 2010; Zhang et al. 2009).
Altogether these data suggest that instead of phylum-level
changes, more subtle changes in the composition of the
intestinal microbiota are associated with the development of
obesity. Recently, Turnbaugh and colleagues have observed
a reduced compositional microbial diversity in obese indi-
viduals compared with lean individuals (Turnbaugh et al.
2009).
It is evident that (excessive) food intake has an influence
on body (over)weight. Recently, a direct link between
intestinal microbiota composition and body weight has
been suggested. One of the first publications that provides
evidence for this link is the publication by Ba¨ckhed and
colleagues for which they colonised germ-free mice with
the microbiota of conventionally raised mice (Ba¨ckhed
et al. 2004). They observed an increase of body fat content
of the colonised germ-free mice despite reduced food
intake, which was suggested to be caused by the intro-
duction of intestinal microbial communities. In a later
study, it was demonstrated that the absence of intestinal
microorganisms protected germ-free mice against the
development of obesity after being fed a high-fat, sugar-
rich diet (Ba¨ckhed et al. 2007). Furthermore, it was
demonstrated that colonisation of germ-free mice with the
microbiota of obese mice induced a significant greater
increase in body fat weight compared with germ-free mice
colonised with the microbiota of lean mice (Turnbaugh
et al. 2006). In addition, these experiments in germ-free
mice have demonstrated that the intestinal microbiota is
involved in the regulation of fat storage. It was shown that
introduction of an intestinal microbiota resulted in an
increase in metabolic rate, modulation of de novo lipo-
genesis and an increase in the uptake of monosaccharides
from the intestine (Ba¨ckhed et al. 2004). Based on these
results, it has been hypothesised that obese individuals are
more efficient in converting food into usable energy and in
storing this energy in fat than lean individuals (Turnbaugh
et al. 2006). As discussed above, the intestinal microbiota
has a crucial role in the digestion of food, in particular the
metabolism of polysaccharides and oligosaccharides and
the production of SCFA that provide the host with addi-
tional amounts of energy. Altered representation of bacte-
rial genes and metabolic pathways, including those
involved in nutrient harvest, were found to be related to
obesity (Turnbaugh et al. 2009). The results from this study
demonstrate that major insights in the differences between
various physiological states of the host (in this case obese
vs. lean) can be obtained by studying the functional
microbial diversity in addition to phylogenetic diversity. In
line with this conclusion is the observation that the amount
of SCFA produced by the intestinal microbiota rather than
the changes in the composition of the microbiota are
important in the development of obesity (Schwiertz et al.
2010).
As for IBD and IBS, which were discussed above, also
for obesity the question remains whether dysbiosis of the
intestinal microbiota is a direct cause for obesity or whe-
ther it reflects a disturbed host environment. It needs to be
established whether the changes in the intestinal microbial
communities in obese individuals are not merely an adap-
tation to a change in the host’s diet. Some of the studies
that have shown an altered composition of the intestinal
microbiota in obese individuals, have also incorporated
analysis of the effect of diet change on the observed dys-
biosis (Table 4) (Duncan et al. 2007, 2008; Ley et al. 2006;
Nadal et al. 2009; Santacruz et al. 2009). Little is known,
however, about the influence of dietary change on micro-
biota composition in humans. A recent study demonstrated
rapid and reversible changes in the relative abundance of
specific dominant bacterial groups after dietary changes
(Walker et al. 2011a). Most striking was the strong increase
in the relative abundance of Ruminococcus bromii and
Eubacterium rectale phylotypes as result of a diet rich in
resistant starch. It was suggested that indigestible dietary
polysaccharides can substantially change the composition
of the intestinal microbiota, however, it is likely that this
depends on the initial composition of the intestinal
microbiota. Interestingly, R. bromii and E. rectale were
identified as key degraders of starch in an in vitro model of
the human colon, using 16S rRNA-based stable isotope
probing (Kovatcheva–Datchary et al. 2009). Recent studies
in mice show that the influence of the diet (high-fat vs.
standard chow or low-fat) on the composition of the
intestinal microbiota is independent of genetic disposition
for obesity (Hildebrandt et al. 2009; Murphy et al. 2010).
In addition to obesity, it has also been suggested that the
intestinal microbiota is involved in obesity-associated
metabolic disorders, such as type 2 diabetes metabolic
endotoxemia, low-grade inflammation and adiposity (Cani
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Table 4 Overview of human studies that demonstrate an association between obesity and compositional dysbiosis of the intestinal microbiota
determined with culture-independent methods
Study
material
Population Analytical methods Key findings References
Faeces
(3 time points)








Ley et al. (2006)
Faeces
(3 time points)
19 Obese individuals (on diet) FISH
GC
Obese individuals on diet of
decreased carbohydrate intake:
; Roseburia










































Faeces 20 Obese individuals













adolescents (on diet and
physical activity)
FISH/flow cytometry Obese individuals:
: C. histolyticum
: E. rectale-C. coccoides
Upon calorie restricted diet:
; C. histolyticum
; C. lituseburense
; E. rectale-C. coccoides
: Bacteroides-Prevotella group




adolescents (on diet and
physical activity)
qPCR Obese adolescents on diet with a
high weight-loss:
: Total bacteria
: B. fragilis group
: C. leptum group
: B. catenulatum group
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and Delzenne 2009; Ley 2010; Vrieze et al. 2010). In a
recent study, a high-throughput sequencing approach was
used to demonstrate that type 2 diabetes, a metabolic dis-
ease primarily caused by obesity-linked insulin resistance,
is associated with changes in the composition of the
intestinal microbiota (Larsen et al. 2010). The relative
abundance of Firmicutes was significantly lower in dia-
betic patients compared with non-diabetic persons. On the
other hand, the Bacteroidetes and Proteobacteria were
present in higher abundance. In addition, the Bacteroidetes/
Firmicutes and Bacteroides-Prevotella/C.coccoides-E.rec-
tale ratios were positively and significantly correlated with
plasma glucose levels.
Microbial diversity and other human diseases
In addition to IBD, IBS and obesity, the intestinal micro-
biota has also been suggested to be involved in several
other (chronic) diseases and disorders. Associations have
been described between intestinal microbial dysbiosis and
intestinal diseases such as coeliac disease, colorectal
cancer, pouchitis and necrotizing enterocolitis (NEC)
(Table 5). The most recent data show that the intestinal
microbiota of coeliac disease patients displays a greater
diversity than healthy controls with higher numbers of
Bacteroides-Prevotella (De Palma et al. 2010; Schippa




Population Analytical methods Key findings References
Faeces
(2 time points)
31 Monozygotic twin pairs
23 Dizygotic twin pairs














Faeces 3 Obese individuals












Zhang et al. (2009)













16 Infants of overweight
women
































All studies have used the body mass index (BMI) to define normal weight, overweight and obesity. Studies that have used subjects from the same
cohort are indicated by *, # and 
FISH fluorescence in situ hybridisation, GC gas chromatography, qPCR quantitative polymerase chain reaction
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Table 5 Overview of human studies that demonstrate an association between intestinal disease and compositional dysbiosis of the intestinal
microbiota
Study material Population Analytical methods Reference
Coeliac disease
Faeces 26 Coeliac patients (no diet, active disease)
23 Children without gluten intolerance
Conventional culturing
FISH
Collado et al. (2007)
Duodenal biopsies 20 Coeliac patients (no diet, active disease)
10 Coeliac patients (gluten-free diet,
symptom-free)
8 Children without gluten intolerance
FISH/flow cytometry Nadal et al. (2007)
Faeces 10 Coeliac patients (no diet, active disease)
10 Children without gluten intolerance
DGGE Sanz et al. (2007)
Duodenal biopsies
faeces
30 Coeliac patients (no diet)
18 Coeliac patients (gluten-free diet)
30 Children without gluten intolerance
qPCR Collado et al. (2008a)
Faeces 24 Coeliac patients (no diet, active disease)
18 Coeliac patients (gluten-free diet,
symptom-free)
20 Children without gluten intolerance
FISH/flow cytometry De Palma et al. (2010)
Duodenal biopsies 20 Coeliac patients (active disease/
symptom-free)
10 Children without gluten intolerance
TGGE Schippa et al. (2010)
Colorectal cancer
Faeces 18 Patients with polyps
32 Individuals with high -risk for colon cancer
38 Individuals with low-risk for colon cancer
Conventional culturing Moore and Moore (1995)
Faeces 13 Patients at high risk for sigmoid colon cancer
14 Healthy individuals
Conventional culturing Kanazawa et al. (1996)
Faeces (3 time points) 20 Colon cancer patients
20 Polypectomized patients
20 Healthy individuals
DGGE Scanlan et al. (2008)
Colorectal biopsies 21 Individuals with adenomas
23 Individuals without adenomas
T-RFLP
Clone library sequencing (16S)
FISH





12 Patients with pouchitis
14 Patients with indeterminable pouchitis
23 Patients without pouchitis
20 Ileostomy patients
9 Healthy individuals
Conventional culturing Onderdonk et al. (1992)
Pouch effluent 5 Patients with pouchitis
9 Patients without pouchitis
Conventional culturing Ruseler-van Embden et al.
(1994)
Pouch effluent UC patients:
8 Patients with healthy pouches
9 Patients, no active pouchitis for at least 1 year
9 Patients, no active pouchitis for at least 6 weeks
11 Patients with pouchitis, on antibiotic treatment
8 Patients with pouchitis
FAP patients:
5 Patients with healthy pouches
Conventional culturing Ohge et al. (2005)
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lituseburense and F. prausnitzii were less abundant in
coeliac disease patients (De Palma et al. 2010). Also in the
case of colorectal cancer, the bacterial diversity and rich-
ness was observed to be higher in patients compared with
healthy controls (Shen et al. 2010). In addition, the intes-
tinal microbiota composition of colorectal cancer patients
differs from that of healthy controls, however, no consis-
tent pattern has yet been observed.
The mucosal and faecal microbiota of UC pouchitis
patients contained more Clostridium and Eubacterium and
fewer Lactobacillus and Streptococcus genera compared
with the microbiota of healthy pouches from familial
adenomatous polyposis (FAP) patients (Lim et al. 2009;
Zella et al. 2011). Luminal samples of UC pouchitis
patients contained more Firmicutes and Verrucomicrobia
and fewer Bacteroidetes and Proteobacteria compared
with FAP patients.
The overall microbiota profiles of premature infants
with necrotizing enterocolitis (NEC) were not distin-
guishable from that of control subjects, but 16S rRNA gene
sequence analysis detected Citrobacter-like sequences and
an increased frequency of Enterococcus-like sequences
(Mshvildadze et al. 2010).
Intestinal microbial dysbiosis has also been observed in
extra-intestinal diseases such as atopic and allergic dis-
eases, autism, type 2 diabetes and rheumatoid arthritis
(Table 6). In children who develop an allergic disease later
in life, a reduced diversity of faecal microbiota was already
observed at 1 week of age (Wang et al. 2009; Niers et al.,
personal communication). During the first 2 months of life,
they were less often colonised with lactobacilli group I
(L. rhamnosus, L. casei, L. paracasei), B. adolescentis and
Clostridium difficile (Kallioma¨ki et al. 2001; Sjo¨gren et al.
2009).
The number of Clostridium species found in the stools
of children with autism was greater than in the stools of
control children, specifically of the C. histolyticum group
(Clostridium clusters I and II) (Finegold et al. 2002; Par-
racho et al. 2005). Bacteroidetes was found at high levels
in the severely autistic children while populations of the
Bifidobacterium genus were reduced (Finegold et al. 2010).
Firmicutes and Clostridia are reduced in type 2 diabetes
(Larsen et al. 2010). Furthermore, the Bacteroidetes/Fir-
micutes ratio as well as Bacteroides-Prevotella/C. cocco-
ides-E. rectale ratio were observed to be correlated with
plasma glucose concentration. In a Chinese population of
diabetes patients, reduced populations of bifidobacteria
were found (Wu et al. 2010).
In comparison to patients with fibromyalgia, patients
with rheumatoid arthritis had significantly less bifidobac-
teria and bacteria of the Bacteroides-Prevotella group,
Bacteroides fragilis subgroup, and E. rectale-C. coccoides
group (Vaahtovuo et al. 2008).
Almost all of the diseases and disorders mentioned
above are largely undefined and have a heterogeneous
aetiology, which makes it difficult to relate changes in
Table 5 continued
Study material Population Analytical methods Reference
Pouch effluent 9 Patients with pouchitis (UC)
13 Patients with healthy pouches (UC)




5 Patients with pouchitis (UC)
15 Patients with healthy pouches (UC)
13 Healthy individuals
LH-PCR
Clone library sequencing (16S)
Komanduri et al. (2007)
Pouch effluent 5 Patients with pouchitis (UC)
15 Patients with healthy pouches (UC)
T-RFLP
Clone library sequencing (16S)
Lim et al. (2009)
Pouch contents
Pouch biopsies
9 Patients with pouchitis (UC)
3 Patients with healthy pouches (UC)
7 Patients with healthy pouches (FAP)
T-RFLP
Clone library sequencing (16S)
Zella et al. (2011)
Necrotizing enterocolitis
Faeces 10 Preterm infants with NEC
10 Preterm infants without NEC
T-RFLP
Clone library sequencing (16S)
Wang et al. (2009)
Faeces (several time
points)
6 Preterm infants with NEC or suspected sepsis
6 Preterm control infants
DGGE
454 FLX titanium sequencing
(16S)
Mshvildadze et al. (2010)
The intestinal diseases IBD, IBS and obesity are discussed separately in the article
DGGE denaturing gradient gel electrophoresis, FAP familial anastomosis polyposis, FISH fluorescence in situ hybridisation, LH-PCR length
heterogeneity polymerase chain reaction, qPCR quantitative polymerase chain reaction, T-RFLP terminal-restriction fragment length poly-
morphism, TGGE temperature gradient gel electrophoresis, UC ulcerative colitis
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microbiota composition and diversity to disease. Again,
also for all these diseases the causality argument of the
observed microbiota changes is unresolved. Ultimately,
causality and knowledge of the underlying mechanisms
will be crucial for a full understanding of the role of the
intestinal microbiota in the aetiology of specific diseases.
Table 6 Overview of human studies that demonstrate an association between extra-intestinal disease and compositional dysbiosis of the
intestinal microbiota
Study material Population Analytical methods References
Atopic and allergic diseases
Faeces 27 Allergic children
36 Non-allergic children
Conventional culturing Bjo¨rkste´n et al. (1999)
Faeces
(5 time points)
18 Infants who developed allergy
26 Infants who remained non-allergic
Conventional culturing Bjo¨rkste´n et al. (2001)
Faeces
(2 time points)
76 Infants at high risk for atopic disease Conventional culturing
FISH
Kallioma¨ki et al. (2001)
Faeces
(2/3 time points)
27 Infants with atopic dermatitis
10 Infants without atopic dermatitis
Conventional culturing
FISH
Kirjavainen et al. (2001)
Faeces 30 Children with atopic dermatitis
68 Children without atopic dermatitis
Conventional culturing Watanabe et al. (2003)
Faeces 957 Infants qPCR Penders et al. (2007)
Faeces 20 Allergic children
20 Non-allergic children





qPCR Suzuki et al. (2007)
Faeces 37 Infants with atopic dermatitis
24 Infants without atopic dermatitis
TGGE
FISH/flow cytometry
Gore et al. (2008)
Faeces 15 Infants who developed atopic dermatitis
20 Infants who remained without atopic dermatitis
T-RFLP
TGGE
Wang et al. (2008)
Faeces
(3 time points)
16 Infants who developed allergy
31 Infants who remained non-allergic








16S rRNA gene sequencing
Finegold et al. (2002)
Faeces 15 Autistic children
8 Non-autistic children
qPCR Song et al. (2004)
Faeces 58 Autistic children
12 Non-autistic siblings
10 Non-autistic children
FISH Parracho et al. (2005)
Faeces 33 Autistic children
7 Non-autistic siblings
8 Non-autistic children
454 FLX titanium sequencing (16S) Finegold et al. (2010)
Diabetes type 2




Wu et al. (2010)
Faeces 18 Type 2 diabetic patients
18 Non-diabetic individuals
qPCR
454 FLX titanium sequencing (16S)
Larsen et al. (2010)
Rheumatoid arthritis
Faeces 51 Patients with early rheumatoid arthritis
50 Patients with fibromyalgia
FISH/flow cytometry Vaahtovuo et al. (2008)
DGGE denaturing gradient gel electrophoresis, FISH fluorescence in situ hybridisation, qPCR quantitative polymerase chain reaction, T-RFLP
terminal-restriction fragment length polymorphism, TGGE temperature gradient gel electrophoresis
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Modulation of the intestinal microbiota
Since it is known that the intestinal microbiota plays an
important role in human health and disease, manipulation
of these microorganisms by antibiotics, probiotics, pre-
biotics and synbiotics are attractive approaches to improve
and maintain health (Gareau et al. 2010; Preidis and
Versalovic 2009).
Antibiotics are widely used as antimicrobial agents to
treat bacterial infections caused by pathogenic micro-
organisms. In general, however, antibiotics (even narrow-
spectrum antibiotics) do not only affect pathogens, but also
commensal intestinal microbial communities. This can
result in dysbiosis of the intestinal microbiota, subse-
quently leading to intestinal problems, such as antibiotic-
associated diarrhoea (AAD) (McFarland 1998). The anti-
biotic-induced disturbances in microbiota composition can
be temporary, returning to its original composition within
2 months, but recently also medium and long-term distur-
bances in (specific) microbial communities have been
described (Dethlefsen et al. 2008; Jernberg et al. 2007,
2010; Koning et al. 2010). An additional problem of the
widespread antibiotic use, is the increased prevalence of
antibiotic resistance resulting from the transfer of antibiotic
resistance genes amongst microorganisms (Jernberg et al.
2010).
The intestinal microbiota can be modulated in a more
biological manner by the use of probiotics. According to
the definition formulated by the World Health Organisation
(WHO) probiotics are ‘live microorganisms which, when
administered in adequate amounts, confer a health benefit
on the host’ (FAO/WHO 2002). Moreover, prebiotics are
used to manipulate the microbiota composition in the GI
tract. The definition of prebiotics is even more generic than
the one of probiotics: ‘non-digestible food ingredients that,
when consumed in sufficient amounts, selectively stimulate
the growth and/or activity(ies) of one or a limited number
of microbial genus(era)/species in the gut microbiota that
confer(s) health benefits to the host’ (Roberfroid et al.
2010). Mixtures of both probiotics and prebiotics are
referred to as synbiotics.
The final part of this review will focus on probiotics as a
way to modulate the intestinal microbiota. The opportuni-
ties for probiotic intervention in maintaining and restoring
health are increasingly being acknowledged, and the field
of probiotic research has grown significantly during the
past few years (Gareau et al. 2010; Ng et al. 2009; Rijkers
et al. 2010).
An introduction to probiotics
In line with the very generic definition of probiotics, many
different microorganisms have been studied for their
potential use as a probiotic, in relation with a wide range of
biological or clinical effects. Most of the microorganisms
that have been studied are naturally present in the human
GI tract. At this moment, the most commonly used pro-
biotic microorganisms belong mainly to the bacterial
genera Lactobacillus and Bifidobacterium (Boesten and De
Vos 2008; Kleerebezem and Vaughan 2009). These two
genera contain a large number of species and strains of
which many are being used as probiotic strains. In addition
to these genera, the probiotic market contains members
from some additional lactic acid bacterial genera, such as
Streptococcus and Enterococcus, and members from the
genera Bacillus and Propionibacterium. Furthermore, some
gram-negative bacteria (e.g. E. coli Nissle 1917) and yeast
(e.g. Saccharomyces) are being used as probiotic micro-
organisms (Gareau et al. 2010; Holzapfel et al. 1998;
Iannitti and Palmieri 2010).
Numerous health-beneficial effects have been attributed
to probiotic microorganisms (Iannitti and Palmieri 2010;
Ng et al. 2009). In general, these health benefits can be
categorised into three levels of probiotic action (Rijkers
et al. 2010). First of all, probiotic microorganisms can act
directly within the GI tract (level 1), for example by direct
interaction with the intestinal microbiota or by enzymatic
activities. Secondly, they can interact directly with the
intestinal mucus layer and epithelium (level 2), thereby
influencing the intestinal barrier function and the mucosal
immune system. Thirdly, probiotics can have effects out-
side the GI tract (level 3), for example on the systemic
immune system and other organs, such as the liver and the
brain. Although in vivo data are emerging, most of the
mechanistic studies with probiotic microorganisms have
been performed in vitro, ex vivo or with the aid of animal
models. The in vitro activity of a given probiotic does not
necessarily correlate with the efficacy of the intended
clinical in vivo. In addition, it is important to note that each
probiotic strain has its own specific properties. The health
benefits that can be attributed to one probiotic strain cannot
be extrapolated to other probiotic strains or mixtures of
strains. Even closely related microbial strains of the same
species may have different physiological effects (Medina
et al. 2007; Meijerink et al. 2010; Lo´pez et al. 2010; Snel
et al. 2010; Van Hemert et al. 2010; Vissers et al. 2010,
2011).
Nowadays, multistrain or multispecies probiotic mix-
tures, which contain more than one probiotic strain, are
becoming increasingly popular (Chapman et al. 2011;
Timmerman et al. 2004). Compared with single strain
probiotics, probiotic mixtures have the possible advantage
that the properties of single strains may have additive or
even synergistic effects when put in a mixture together
with other probiotics strains, which can result in higher
efficacy. Another potential advantage of probiotic mixtures
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may be that compared with a single strain probiotic a wider
range of health benefits could be accomplished. In contrast,
mixing of probiotic strains might also result in reduced
efficacy since individual strains may have opposite effects
or even inhibit each other. There are, however, a limited
number of in vivo studies available that compare the effects
of a probiotic mixture with those of the individual strains
(Chapman et al. 2011). This means that the evidence for the
hypothesis that probiotic mixtures are more effective than
the individual strains is still limited.
The influence of probiotics on the composition
and diversity of the intestinal microbiota
Modulation of the intestinal microbiota (part of level 1
probiotic action) is one of the potential health-beneficial
effects of probiotics. The mechanisms by which probiotic
microorganisms are able to modify the intestinal micro-
biota include reduction of luminal pH, competition for
nutrients, secretion of anti-microbial compounds (bacteri-
ocins), prevention of bacterial adhesion and evasion of
epithelial cells, and induction of the production of anti-
microbial compounds (defensins) by the host (Fooks and
Gibson 2002; Ng et al. 2009). By these mechanisms, pro-
biotics can not only potentially modulate the intestinal
microbiota composition, but also prevent pathogenic
bacterial overgrowth.
Up to this date, many studies have been performed that
examine the effects of probiotics on the composition and
diversity of the intestinal microbiota, both in diseased and
healthy individuals. For a given disease, the desired out-
come of probiotic intervention is the modulation of the
intestinal microbiota in such a way that a healthy micro-
biota composition is achieved. However, also other
parameters have been addressed such as stabilisation of the
microbiota as in the case of IBS and a multispecies pro-
biotic, determined with the use of a phylogenetic micro-
array (Kajander et al. 2008). The interpretation of the
effects of probiotics on the intestinal microbiota composi-
tion in healthy individuals are, however, more difficult to
interpret (Table 7). Those studies do provide information
on the effects of probiotics on the intestinal microbiota
without a potential bias caused by disease effects. How-
ever, this does not imply that in a diseased situation these
probiotic products will have the same influence on the
intestinal microbiota.
Until recently, in most of the probiotic studies conven-
tional culture-based methods have been used to study the
influence of probiotics on the intestinal microbiota. How-
ever, since a few years culture-independent methods are
now also being applied in probiotic research (Table 7). In
general, demonstrating the colonisation of the supple-
mented probiotic microorganism(s) has been the primary
aim of most studies in healthy individuals. In most cases, a
transient colonisation of the probiotic microorgan-
ism(s) has been observed. It is still questionable, however,
whether probiotic strains would need to colonise in order
to be effective or whether transient presence would also
suffice to exert health-beneficial effects.
The probiotic studies performed in humans have almost
exclusively examined the effect of probiotic administration
on the composition of the faecal microbiota, whereas other
niches of the GI tract have hardly been studied thus far
(Table 7). As already indicated, even major local changes
in microbiota composition in specific niches of the GI tract
might not be reflected in the faeces. This means that there
is still a major gap in knowledge on the influence of pro-
biotic microorganisms on the intestinal microbiota. In
addition, the influence of probiotic microorganisms on
mucosa-associated intestinal microbiota is also not well
studied. However, these interactions are possibly of key
importance in relation to disease pathogenesis, since
mucosa-associated microorganisms are in more close
contact with the intestinal barrier and immune system. One
of the few examples of a study on the in vivo effects of
probiotics on the human host is a recent study by Van
Baarlen et al. (2009). The authors examined the influence
of a probiotic microorganism on human duodenal mucosal
gene expression and they showed that changes in gene
expression patterns, especially in the NF-jb dependent
pathways, induced by Lactobacillus plantarum WCFS1
could be linked to the establishment of immunotolerance in
human adults.
In contrast with most human probiotic studies, animal
studies have focused on the spatial influence of probiotics
on the intestinal microbiota (Table 7). However, to which
extent these results reflect the human situation has to be
determined. Administration of a given probiotic strain will
result in the (temporarily) increase of that strain the GI
tract, but may also change the overall composition of the
intestinal microbiota. Indeed, the results of relevant
experiments performed thus far demonstrate that probiotic-
induced changes in microbiota composition are not
restricted to the administered species. Which probiotic
microorganisms are able to influence the relative abun-
dance of which specific intestinal microorganisms are
questions that are currently under study. It should be
realised, however, that a change in composition or diversity
of the intestinal microbiota by probiotic intervention is not
a health benefit by itself.
As discussed previously, dysbiosis of the intestinal
microbiota has been associated with a growing number of
(intestinal) diseases. Since modulation of the composition
of intestinal microbiota by probiotics was demonstrated to
be possible, probiotic intervention has the potential to
counterbalance intestinal dysbiosis and thus restore health.
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Table 7 Details of studies performed to examine the effects of probiotic intervention on intestinal microbiota composition of healthy subjects
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The effectiveness of probiotic intervention has been stud-
ied in a number of human diseases, including IBD (CD, UC
and pouchitis), IBS, constipation, diarrhoea (including
AAD), colon cancer, cardiovascular disease, NEC, allergic
diseases, obesity and metabolic disorders and these have
been the subject of systematic reviews as well as Cochrane
reviews (Gareau et al. 2010; Iannitti and Palmieri 2010;
Pham et al. 2008; Sanz et al. 2010; Weichselbaum 2010).
With the possible exception of NEC and pouchitis, variable
clinical effects are found. One, and probably the most
important reason for the variable clinical effects is the
variation in probiotic species and strains that are being
used. On top of that, there is a lack of standardised methods
for the study of the intestinal microbiota (e.g. sample col-
lection, sample storage and analysis methods), which
makes it almost impossible to directly compare findings
from different groups. Apart from the large variety of
probiotic species and strains, also different dosages of
probiotic microorganisms are used, or combinations of
probiotic species and strains, or prebiotic supplements can
be added. In addition, the populations of interest can be
relatively heterogeneous since health and disease are not
always well defined. At the same time, host-dependent
factors (e.g. host genotype) may have an influence on the
effectiveness of intestinal microbiota modulation by pro-
biotics. Finally, most clinical studies have included only a
small number of patients and used short-term intervention
periods. All of this, in combination with the fact that the
intestinal microbiota composition is diverse and maybe
even unique for each individual, makes it problematic to
observe general changes in microbiota composition as
result of probiotic intervention.
In the early days of probiotic research, it was thought
that decreased intestinal microbial diversity could be a
direct cause of gastrointestinal disease. In such a concept,
probiotic intervention should be aimed at increasing this
diversity, which would be sufficient to resolve the clinical
problem. For some diseases such as IBD, there is indeed
evidence for a decreased diversity (Dicksved et al. 2008;
Nishikawa et al. 2009; Qin et al. 2010). By contrast, a
recent culture-independent study shows a higher richness
and diversity of bacteria in the faeces of autistic individuals
compared with healthy controls (Finegold et al. 2010).
Nowadays, it is recognised that the interaction between
intestinal microbiota and the host is more complex than just
a high or low microbial diversity. Thus, no general state-
ments can be made on the role of microbial diversity in
health and disease, since different microbe-host inter-
actions are involved in the pathophysiology of different
diseases. Knowledge of the molecular and physiological
mechanisms behind specific diseases and aberrations that
are associated with microbial dysbiosis will contribute to
the development of tailor-made probiotics designed for
specific interventions.
Application of high-throughput molecular approaches
in probiotic research
New insights in the potential effect of probiotic interven-
tion on the intestinal microbiota can be obtained by
application of high-throughput molecular approaches in
probiotic research. An example is provided by a study in
which the effectiveness of daily probiotic supplementation
of Lactobacillus rhamnosus GG (LGG) on preventing
the development of early markers of asthma in a human
clinical study was examined (Cabana et al. 2007). The
probiotic bacterium LGG is one of the most widely used
probiotic microorganisms and has been used in a large
number of clinical trials. An explanation for its probiotic
properties has recently been provided by its genomic
characterisation revealing the presence of mucus binding
pili in LGG that are assumed to interact with the host
(Kankainen et al. 2009). A phylogenetic microarray ana-
lysis was used to study the effect of LGG abundance on the
bacterial community structure of stool samples of 6-month-
old infants (Cox et al. 2010). Since the researchers were
blinded to the treatment of the infants (probiotic or pla-
cebo), the effect of LGG administration on LGG abun-
dance and intestinal microbiota composition could not be
examined. However, cluster analysis of the microarray data
demonstrated that LGG abundance was associated with a
distinct community composition. Communities with high
relative abundance of LGG showed an increased relative
abundance of a large number of bacterial taxa and the
majority of these taxa were phylogenetically clustered. In
addition, there was a significant difference in evenness of
the intestinal microbiota between samples containing a low
or high abundance of LGG. It was hypothesised that a
possible mechanism of the probiotic action of LGG is the
stimulation of a stable, even and functionally redundant
microbiota and facilitating the colonisation by other
beneficial microorganisms (Kankainen et al. 2009).
Whether the ability of pili of LGG to bind to intestinal
mucosal surfaces is important in this respect remains to be
determined.
Recently, high-throughput metagenomic sequencing
was used to relate the effect of probiotic intervention to
microbiota composition (Veiga et al. 2010). It was dem-
onstrated that consumption of a fermented milk product
supplemented with Bifidobacterium animalis subsp. lactis
(BFMP) induced some specific metabolic shifts in an
ulcerative colitis mouse model. In addition, it was shown
that the immune status of the mice had an effect on the
shifts in the composition of the intestinal microbiota.
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Moreover, subsets of mice could be identified based on
microbiota composition that clustered together corre-
sponding to effectiveness of the BFMP treatment. These
results reinforce the notion that the composition of the
endogenous intestinal microbiota plays an important role in
the host response to the probiotic intervention, thereby
influencing the effectiveness of probiotic intervention. In
this study, it was also observed that BFMP consumption
resulted in a metabolic shift; a decreased caecal pH and
alteration in short- chain fatty acid profiles. It must be
noted, however, that these beneficial effects cannot be
directly linked to the activity of this specific Bifidobacte-
rium strain since a non-fermented milk product was used as
control product. Overall, the data support the hypothesis
that probiotics are not only able to influence the compo-
sition, but also the metabolic activity of the intestinal
microbiota (De Preter et al. 2010). Both of these effects
need to be studied separately to get a complete picture of
the influence of probiotic intervention on the intestinal
microbiota. This is also emphasised in a recent study in
which the effect of a specific synbiotic product on the
intestinal microbiota was examined (Vitali et al. 2010).
This study showed no influence on the composition of
dominant faecal microbiota, but significant changes in
faecal metabolic profiles were observed. These results
suggest that synbiotic intervention is able to affect the
metabolic activity of the intestinal microbiota while
maintaining microbiota composition with respect to its
predominant components.
Conclusions
Knowledge on the composition and diversity of a healthy
microbiota and on how changes in the intestinal microbiota
lead to or are associated with disease, is far from complete.
More research is needed to examine the species and strain
diversity in the GI tract, the diversity of microbial genes
(microbiome) in the GI tract and the activity of these genes
(mRNA, protein and metabolite production). For future
probiotic research it is important to determine the level of
compositional and functional microbial dysbiosis in rele-
vant target populations and identify potential members of
the healthy microbiota to counteract the dysbiosis.
Understanding the molecular mechanisms of action attrib-
uted to commensal and pathogenic bacteria will contribute
to better designed probiotic products. In the future, this
knowledge can be applied in the development of tailor-
made probiotics designed for clearly characterised target
populations.
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